FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168674906> ?p ?o ?g. }

• W2168674906 endingPage "1275.e2" @default.
• W2168674906 startingPage "1267" @default.
• W2168674906 abstract "BackgroundThere has been a marked paradigm shift in the treatment of symptomatic femoro-popliteal disease with a shift from open to endoluminal therapy. The consequence of this shift in therapy is poorly described. The aim of this study is to examine the clinical efficacy of this shift in treatment strategies.MethodsA database of patients undergoing open (OPEN) and endoluminal (ENDO) intervention for TASC II C and D femoro-popliteal lesions between 1990 and 2010 was retrospectively queried. Kaplan-Meier survival analyses were performed to assess time-dependent outcomes. Factor analyses were performed using a multivariant Cox proportional hazard model for time-dependent variables.ResultsA total of 2593 limbs underwent either OPEN or ENDO treatment for symptomatic and anatomically advanced femoro-popliteal disease over a 20-year period. There was a two-fold rise in endovascular interventions between the first and second decade. In the first decade, 80% of the interventions were OPEN, while in the second decade, 61% of the interventions were ENDO. There were equivalent comorbidities in both groups, and survival was also equivalent. Endoluminal therapy was more commonly performed on claudicants. Thirty-day mortality was equivalent, but major morbidity was higher in OPEN compared with ENDO. Cumulative patency was equivalent in both groups with a similar reintervention rate. In contrast, clinical efficacy (freedom from recurrent symptoms, maintenance of ambulation, and avoidance of major amputation) was significantly higher in the OPEN group (P = .002). The presence of critical limb ischemia, diabetes, end-stage renal disease, and poor tibial runoff were predictors of poor anatomic and functional outcomes in both groups.ConclusionsThere has been a marked shift in treatment modality for advanced femoro-popliteal disease with a lowering of the symptomatic threshold for intervention over 2 decades, likely spurred by the ease of endoluminal interventions. Although peri-procedural and anatomic outcomes for both procedures are equivalent, it appears that open surgery carries a superior long-term clinical efficacy. This superiority is negatively influenced by poor preoperative ambulation status, high modified Cardiac Risk Score, worse presenting symptoms, the occurrence of major adverse cardiovascular events, poor tibial runoff, the absence of hemodynamic success, and occlusion of the original bypass. There has been a marked paradigm shift in the treatment of symptomatic femoro-popliteal disease with a shift from open to endoluminal therapy. The consequence of this shift in therapy is poorly described. The aim of this study is to examine the clinical efficacy of this shift in treatment strategies. A database of patients undergoing open (OPEN) and endoluminal (ENDO) intervention for TASC II C and D femoro-popliteal lesions between 1990 and 2010 was retrospectively queried. Kaplan-Meier survival analyses were performed to assess time-dependent outcomes. Factor analyses were performed using a multivariant Cox proportional hazard model for time-dependent variables. A total of 2593 limbs underwent either OPEN or ENDO treatment for symptomatic and anatomically advanced femoro-popliteal disease over a 20-year period. There was a two-fold rise in endovascular interventions between the first and second decade. In the first decade, 80% of the interventions were OPEN, while in the second decade, 61% of the interventions were ENDO. There were equivalent comorbidities in both groups, and survival was also equivalent. Endoluminal therapy was more commonly performed on claudicants. Thirty-day mortality was equivalent, but major morbidity was higher in OPEN compared with ENDO. Cumulative patency was equivalent in both groups with a similar reintervention rate. In contrast, clinical efficacy (freedom from recurrent symptoms, maintenance of ambulation, and avoidance of major amputation) was significantly higher in the OPEN group (P = .002). The presence of critical limb ischemia, diabetes, end-stage renal disease, and poor tibial runoff were predictors of poor anatomic and functional outcomes in both groups. There has been a marked shift in treatment modality for advanced femoro-popliteal disease with a lowering of the symptomatic threshold for intervention over 2 decades, likely spurred by the ease of endoluminal interventions. Although peri-procedural and anatomic outcomes for both procedures are equivalent, it appears that open surgery carries a superior long-term clinical efficacy. This superiority is negatively influenced by poor preoperative ambulation status, high modified Cardiac Risk Score, worse presenting symptoms, the occurrence of major adverse cardiovascular events, poor tibial runoff, the absence of hemodynamic success, and occlusion of the original bypass." @default.
• W2168674906 created "2016-06-24" @default.
• W2168674906 creator A5003202081 @default.
• W2168674906 creator A5003826396 @default.
• W2168674906 creator A5027120100 @default.
• W2168674906 creator A5039311069 @default.
• W2168674906 creator A5040786364 @default.
• W2168674906 creator A5058887706 @default.
• W2168674906 creator A5076355638 @default.
• W2168674906 creator A5077166214 @default.
• W2168674906 date "2013-11-01" @default.
• W2168674906 modified "2023-10-18" @default.
• W2168674906 title "Current efficacy of open and endovascular interventions for advanced superficial femoral artery occlusive disease" @default.
• W2168674906 cites W1965923350 @default.
• W2168674906 cites W1967179207 @default.
• W2168674906 cites W1971064841 @default.
• W2168674906 cites W1984684769 @default.
• W2168674906 cites W2015745956 @default.
• W2168674906 cites W2025119733 @default.
• W2168674906 cites W2033779922 @default.
• W2168674906 cites W2043517681 @default.
• W2168674906 cites W2044381705 @default.
• W2168674906 cites W2046953232 @default.
• W2168674906 cites W2051542500 @default.
• W2168674906 cites W2057398300 @default.
• W2168674906 cites W2061430769 @default.
• W2168674906 cites W2071356282 @default.
• W2168674906 cites W2079477603 @default.
• W2168674906 cites W2092082358 @default.
• W2168674906 cites W2110843198 @default.
• W2168674906 cites W2122523807 @default.
• W2168674906 cites W2123037059 @default.
• W2168674906 cites W2123289485 @default.
• W2168674906 cites W2144985796 @default.
• W2168674906 cites W4241087134 @default.
• W2168674906 doi "https://doi.org/10.1016/j.jvs.2013.02.252" @default.
• W2168674906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24160311" @default.
• W2168674906 hasPublicationYear "2013" @default.
• W2168674906 type Work @default.
• W2168674906 sameAs 2168674906 @default.
• W2168674906 citedByCount "20" @default.
• W2168674906 countsByYear W21686749062014 @default.
• W2168674906 countsByYear W21686749062015 @default.
• W2168674906 countsByYear W21686749062016 @default.
• W2168674906 countsByYear W21686749062017 @default.
• W2168674906 countsByYear W21686749062018 @default.
• W2168674906 countsByYear W21686749062019 @default.
• W2168674906 countsByYear W21686749062020 @default.
• W2168674906 countsByYear W21686749062021 @default.
• W2168674906 countsByYear W21686749062022 @default.
• W2168674906 crossrefType "journal-article" @default.
• W2168674906 hasAuthorship W2168674906A5003202081 @default.
• W2168674906 hasAuthorship W2168674906A5003826396 @default.
• W2168674906 hasAuthorship W2168674906A5027120100 @default.
• W2168674906 hasAuthorship W2168674906A5039311069 @default.
• W2168674906 hasAuthorship W2168674906A5040786364 @default.
• W2168674906 hasAuthorship W2168674906A5058887706 @default.
• W2168674906 hasAuthorship W2168674906A5076355638 @default.
• W2168674906 hasAuthorship W2168674906A5077166214 @default.
• W2168674906 hasBestOaLocation W21686749061 @default.
• W2168674906 hasConcept C126322002 @default.
• W2168674906 hasConcept C134018914 @default.
• W2168674906 hasConcept C141071460 @default.
• W2168674906 hasConcept C207103383 @default.
• W2168674906 hasConcept C2776204877 @default.
• W2168674906 hasConcept C2777303625 @default.
• W2168674906 hasConcept C2777466421 @default.
• W2168674906 hasConcept C2778213512 @default.
• W2168674906 hasConcept C2781099653 @default.
• W2168674906 hasConcept C3018348675 @default.
• W2168674906 hasConcept C44249647 @default.
• W2168674906 hasConcept C50382708 @default.
• W2168674906 hasConcept C555293320 @default.
• W2168674906 hasConcept C71924100 @default.
• W2168674906 hasConceptScore W2168674906C126322002 @default.
• W2168674906 hasConceptScore W2168674906C134018914 @default.
• W2168674906 hasConceptScore W2168674906C141071460 @default.
• W2168674906 hasConceptScore W2168674906C207103383 @default.
• W2168674906 hasConceptScore W2168674906C2776204877 @default.
• W2168674906 hasConceptScore W2168674906C2777303625 @default.
• W2168674906 hasConceptScore W2168674906C2777466421 @default.
• W2168674906 hasConceptScore W2168674906C2778213512 @default.
• W2168674906 hasConceptScore W2168674906C2781099653 @default.
• W2168674906 hasConceptScore W2168674906C3018348675 @default.
• W2168674906 hasConceptScore W2168674906C44249647 @default.
• W2168674906 hasConceptScore W2168674906C50382708 @default.
• W2168674906 hasConceptScore W2168674906C555293320 @default.
• W2168674906 hasConceptScore W2168674906C71924100 @default.
• W2168674906 hasIssue "5" @default.
• W2168674906 hasLocation W21686749061 @default.
• W2168674906 hasLocation W21686749062 @default.
• W2168674906 hasOpenAccess W2168674906 @default.
• W2168674906 hasPrimaryLocation W21686749061 @default.
• W2168674906 hasRelatedWork W1986536275 @default.
• W2168674906 hasRelatedWork W2009704097 @default.
• W2168674906 hasRelatedWork W2052981426 @default.
• W2168674906 hasRelatedWork W2089825344 @default.
• W2168674906 hasRelatedWork W2126853518 @default.

• next